









Markets
/
Stocks
/
nasdaq-aemd
/

Aethlon Medical Inc

AEMD

0.728USD

-0.052-6.67%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

1.89MMarket Cap

LossP/E TTM



Aethlon Medical Inc

0.728

-0.052-6.67%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

119 / 207

Overall Ranking

275 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

3.025

Target Price

+287.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Overvalued

The company’s latest PE is -0.01, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 432.31K shares, decreasing 20.22% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.62.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.83, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.83

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.78

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.92

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.01, which is 475.21% below the recent high of -0.07 and -4200.85% above the recent low of -0.50.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Aethlon Medical Inc is 3.02, with a high of 4.55 and a low of 1.50.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Hold

Current Rating

3.025

Target Price

+315.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Aethlon Medical Inc

AEMD

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.56, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.15 and the support level at 0.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.058

Sell

RSI(14)

40.141

Neutral

STOCH(KDJ)(9,3,3)

59.129

Neutral

ATR(14)

0.149

Low Volatility

CCI(14)

-30.767

Neutral

Williams %R

90.519

Oversold

TRIX(12,20)

-2.385

Sell

StochRSI(14)

18.815

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.750

Sell

MA10

0.729

Sell

MA20

1.089

Sell

MA50

1.194

Sell

MA100

1.050

Sell

MA200

0.784

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 16.72%, representing a quarter-over-quarter decrease of 18.18%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

180.76K

+1.27%

Ikarian Capital LLC

153.66K

-0.00%

Boothbay Fund Management, LLC

44.84K

+65.63%

Geode Capital Management, L.L.C.

15.53K

+12.59%

Rossetti (Angela)

6.21K

-74.20%

Broenniman (Edward G)

3.99K

-82.44%

Shah (Chetan S)

2.14K

-90.19%

Gikakis (Nicolas)

1.78K

-91.82%

UBS Financial Services, Inc.

8.33K

-73.28%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.08, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.